Compare Amphastar Pharmaceuticals Inc (AMPH) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs L3Harris Technologies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while L3Harris Technologies Inc trades at $290 (market cap $54.17B). The key difference: L3Harris Technologies Inc is far larger — about 65.6× Amphastar Pharmaceuticals Inc's market cap, and L3Harris Technologies Inc pays a 1.72% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LHX | |
|---|---|---|
Market Cap | $826.08M | $54.17B |
Sector | Health | Industrials |
52-Week High | $30.81 | $378.48 |
52-Week Low | $16.87 | $259.55 |
Enterprise Value | $1.22B | $64.94B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
LHX trades at $290.77, up 0.31% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains a 7.71% net income margin. Recent news includes a $84 million U.S. Army contract for NGC2 manpack systems (Business Wire, July 9, 2026). Cash flow from operations improved to $3.11B in 2025, while debt-to-asset ratio declined to 26.98%.
Outlook is positive with a consensus price target of $367.50, implying 26% upside, supported by 75% analyst buy ratings. Risks include execution delays in defense contracts and macroeconomic pressures. The stock offers value through earnings growth and dividend yield, but investors should monitor debt levels and competitive threats from new entrants like SpaceX.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
